Article Text

Download PDFPDF

LP-074 Cost-of-illness changes before and after diagnosis of systemic lupus erythematosus: a nationwide population-based cohort study in Korea
  1. Hyoungyoung Kim1,
  2. Soo-Kyung Cho1,
  3. Jung-Yong Han1,
  4. Yena Jeon2,
  5. Sun-Young Jung3,
  6. Eun Jin Jang4 and
  7. Yoon-Kyoung Sung1
  1. 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
  2. 2Department of Statistics, Kyungpook National University, Republic of Korea
  3. 3College of Pharmacy, Chung-Ang University, Republic of Korea
  4. 4Department of Information Statistics, Andong National University, Republic of Korea


Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with various ranges of organ damages, so that patients with SLE might face to considerable medical costs in their early disease courses. We aimed to estimate the progression of direct healthcare costs before and after diagnosis of SLE and to compare healthcare costs by disease severity in Korean patients with SLE.

Methods Incident patients with SLE were identified between 2008 and 2018 using the Korean National Health Insurance databases. Annual direct healthcare costs for five years before and after the diagnosis of SLE were estimated and we compared them with those of age-, sex-, and calendar months-matched controls (1:4). Direct healthcare costs of patients with SLE were compared by disease severity using inverse probability-weighted regression analysis.

Results A total of 11,173 incident SLE patients and 45,500 subjects without SLE were identified. Annual direct healthcare costs per person in SLE group was increasing one year before SLE diagnosis, and reached the highest at the first year of SLE diagnosis, resulting 7.7-fold greater than comparators ($5,694 vs. $736 a year, respectively). Among patients with SLE, having severe SLE resulted in 4.39 times (95% Confidence Interval [CI] 4.123–4.673) higher cost over a period of 1 year. Older age (aged 70–79, 1.455 times, 95% CI 1.304–1.623), having comorbidities such as lupus nephritis (1.89 times, 95% CI 1.801–1.983), avascular necrosis (5.482 times, 95% CI 3.977–7.668), chronic kidney diseases (1.783 times, 95% CI 1.601–1.985), and interstitial lung diseases (1.542 times, 95% CI 1.346–1.765) were associated with higher annual direct healthcare costs of the first year.

Conclusions Patients with SLE incurred significantly high direct healthcare costs compared to subjects without SLE, especially during the first year after diagnosis. Disease severity as well as comorbidities were associated with increased costs of illness in patients with SLE.

  • Systemic lupus erythematosus
  • Healthcare cost
  • Disease severity

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.